Telix Pharmaceuticals (TLPPF) Operating Leases (2023 - 2026)

Telix Pharmaceuticals (TLPPF) has reported Operating Leases for 4 consecutive years, with $3.9 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Operating Leases changed N/A year-over-year to $3.9 million in Q2 2026; TTM through Jun 2026 was $3.9 million, a N/A change from a year earlier, with the FY2025 full-year figure at $5.5 million, up 258.86% from the prior year.
• Operating Leases was $3.9 million for Q2 2026 at Telix Pharmaceuticals, down from $5.5 million in the prior quarter.
• Over five years, Operating Leases peaked at $5.5 million in Q4 2025 and troughed at $387339.3 in Q4 2023.
• A 4-year average of $2.9 million and a median of $2.8 million in 2026 frame the typical range for Operating Leases.
• Across the five-year window, Operating Leases soared 321.41% in 2024 and soared 239.89% in 2025, its largest moves.
• Over 4 years, Operating Leases stood at $387339.3 in 2023, then soared by 321.41% to $1.6 million in 2024, then soared by 239.89% to $5.5 million in 2025, then dropped by 29.42% to $3.9 million in 2026.
• The last three Operating Leases figures came in at $3.9 million (Q2 2026), $5.5 million (Q4 2025), and $1.6 million (Q4 2024), per Business Quant data.